TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27043237
Drug: Probiotics (Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bacillus subtilis and Enterococcus faecalis) 0.5 g three times daily through a nasogastric feeding tube plus standard preventive strategies
Study: 12177541
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg methylprednisolone acetate (Depomedrol)
Study: 12177541
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline (control)
Study: 10459686
Drug: Trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 100 mg/day
Study: 10459686
Drug: Trazodone (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-100 mg/day)
Study: 7776455
Drug: Ileal low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal low pressure reservoir using the Goodwin cup‐patch principle combined with an afferent ileal tubular segment
Study: 2772366
Drug: Propranolol (PPL)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PPL) (160‐240 mg/day)
Study: 2772366
Drug: Pindolol (PDL)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (PDL) and Clopamide (CLP) (PDL 10 mg, CLP 5 mg per tablet, 1-3 tablets based on blood pressure response)
Study: 2772366
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) (150‐100 mg/day)
Study: 342149
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate treatment
Study: 30656648
Drug: Routine Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Fluid Treatment (RFT)
Study: 26944938
Drug: Prescription Interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Interactive Voice Response (IVR) Talking Prescriptions (Talking Rx) and SMS reminders
Study: 24566877
Drug: STOPP recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOPP recommendations made by the inpatient geriatric consultation team (IGCT) to ward physicians to discontinue potentially inappropriate medications (PIMs)
Study: 22894574
Drug: Tofacitinib 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 0.5 mg
Study: 22460142
Drug: Tofacitinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 3 mg
Study: 24030917
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg
Study: 23855761
Drug: Tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 15 mg
Study: 17692985
Drug: Pegylated‐interferon plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated‐interferon plus ribavirin (800 mg/day up to 52 weeks)
Study: 17692985
Drug: Genotype 1
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype 1 with low viral load at start of therapy
Study: 15822043
Drug: Ulinastatin (150,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (150,000 U) administered by intravenous infusion for 10 minutes before ERCP
Study: 15822043
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by intravenous infusion for 10 minutes before ERCP
Study: 9084463
Drug: CP-148,623 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-148,623 (300 mg twice a day; n = 12)
Study: 20002061
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g activated charcoal
Study: 31328363
Drug: GLP-1 antagonist
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 antagonist exendin 9-39
Study: 26154030
Drug: EXPL (1.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXPL (1.61 g protein/100 kcal; modified bovine whey proteins with caseinoglycomacropeptide removed)
Study: 26154030
Drug: CTRL (2.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRL (2.15 g protein/100 kcal; unmodified bovine milk protein with a whey/casein ratio of 60/40)
Study: 12721161
Drug: Ovulation induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation induction (OI) with clomiphene (CC) or gonadotrophin (FSH) and intrauterine insemination (IUI)
Study: 9416653
Drug: Neuroleptic dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic dosage reduction (tapered by 25% each month)
Study: 31963802
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD: 13 g of EAAS BID)
Study: 31963802
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD: 8 g of EAAS BID)
Study: 29196046
Drug: Open-label intravenous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label intravenous ceftriaxone 2000 mg in addition to usual care
Study: 12175665
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg intravenous bolus and 1 mg/kg subcutaneous injections twice daily for 3-8 days)
Study: 9635630
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (both doses)
Study: 7653805
Drug: Pancuronium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.15 mg/kg
Study: 31241007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nano‐curcumin (80 mg) plus CoQ10 (300 mg)
Study: 31241007
Drug: Nano‐curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano‐curcumin (80 mg)
Study: 31241007
Drug: CoQ10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (300 mg)
Study: 31241007
Drug: Control (nano‐curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nano‐curcumin and CoQ10 placebo included oral paraffin oil)
Study: 29628182
Drug: Time In
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time In intervention (sensorimotor intervention combining biomechanical physiotherapeutic procedures and psychological strategies, 3h weekly sessions for 5 weeks)
Study: 15711670
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alfa 2b 3 million units 3 times per week plus ribavirin 1000-1200 mg orally per day for 48 weeks
Study: 7859421
Drug: Ceftriaxone 50
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 50 mg/kg (single dose)
Study: 7859421
Drug: Cefaclor 40
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 40 mg/kg/day (10 days)
Study: 2816761
Drug: Theophylline (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (7 mg/kg)
Study: 128475
Drug: Locacorten (0.02%)-Vioform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locacorten (0.02%)-Vioform (3%) cream
Study: 26407753
Drug: Enoxaparin followed
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin followed by warfarin
Study: 24902962
Drug: Oral pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pioglitazone 30 mg daily for 10 weeks
Study: 23132643
Drug: Acidic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic saline (2.5 mL, pH 3.3)
Study: 23132643
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (2.5 mL, pH 6.0)
Study: 11244441
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide (Men PS) vaccine, administered 8 months after BMT (early group; 22 patients)
Study: 11244441
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide (Men PS) vaccine, administered 20 months after BMT (late group; 22 patients)
Study: 11244441
Drug: Meningococcal polysaccharide
Normalized name: meningococcal polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal polysaccharide (Men PS) vaccine, both early and late groups
Study: 9855434
Drug: Three-component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-component acellular vaccine (3-5-12 schedule)
Study: 9855434
Drug: Five-component vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-component vaccine (3-5-12 schedule)
Study: 9855434
Drug: Whole-cell vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell vaccine (3-5-12 schedule)
Study: 9855434
Drug: Multicomponent acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent acellular vaccine (2-4-6 schedule)
Study: 9855434
Drug: Delayed third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed third dose (both schedules)
Study: 31481010
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injection (TEI) with lidocaine and methylprednisolone acetate for L3 and below, and lidocaine with dexamethasone above L3.
Study: 31481010
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral pain medication.
Study: 24995271
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg), amoxicillin/clavulanate (875 mg/125 mg), and rabeprazole (20 mg) twice per day (LAcR)
Study: 24995271
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg), amoxicillin (1000 mg), and rabeprazole (20 mg) twice per day (CAR)
Study: 22766314
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² intravenously day 1 with vitamin B12, folic acid, and dexamethasone
Study: 22766314
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² intravenously day 1 with dexamethasone
Study: 18849664
Drug: DTwP/HB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP/HB vaccine (Q‐Vac) administered alone (Group A)
Study: 18849664
Drug: DTwP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP and HB vaccines at separate sites (Group B)
Study: 18849664
Drug: DTPw/HB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw/HB vaccine (Tritanrix HB) (Group C)
Study: 17719471
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg for 6 weeks
Study: 17719471
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg for 6 weeks
Study: 3319721
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of grenz ray treatment and topical steroid
Study: 3319721
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid alone
Study: 30630789
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefmetazole and traditional excision
Study: 24368363
Drug: Intensive physiotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive physiotherapy (usual care plus two additional 30-minute treatments each day)
Study: 24368363
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (daily physiotherapy treatment, approximately 30 minutes)
Study: 18235122
Drug: Standard-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose imatinib (400 mg daily)
Study: 18235122
Drug: Standard-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose imatinib (400 mg daily) followed by high-dose imatinib (400 mg twice daily) after progression
Study: 15653971
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP), 1,000 microg/d, then reduced to 200 microg/d (group 1)
Study: 15653971
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of FP, 200 microg/d (group 2)
Study: 12608491
Drug: Alcoholic beer
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic beer (8.5%) administered to reach a blood alcohol concentration of 40 mg/dl
Study: 10440421
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily for 10 days
Study: 1316060
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral lomefloxacin 2-6 hours before surgery
Study: 1316060
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g parenteral cefuroxime 30-90 minutes before surgery
Study: 1316060
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral lomefloxacin
Study: 1316060
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g parenteral cefuroxime
Study: 3904259
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated cold‐adapted influenza A vaccines (H1N1 and H3N2)
Study: 26872892
Drug: Ixazomib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib administered after a high-fat meal
Study: 26872892
Drug: Ixazomib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib administered in fasted state
Study: 23315999
Drug: Brief eclectic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief eclectic psychotherapy for PTSD (successful treatment group, n = 10)
Study: 23315999
Drug: Brief eclectic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief eclectic psychotherapy for PTSD (unsuccessful treatment group, n = 10)
Study: 17938943
Drug: Oral chlormadinone
Normalized name: chlormadinone
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlormadinone acetate
Study: 16669976
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/d (FA-5)
Study: 16669976
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 15 mg/d (FA-15)
Study: 12796671
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg fluoxetine once weekly
Study: 11370345
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg aqueous extract powder in 10 mL distilled water
Study: 11370345
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL distilled water (control)
Study: 8841891
Drug: Odontoson M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odontoson M plus an ionized irrigant solution
Study: 3675133
Drug: 0.75 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mL/kg of ethanol
Study: 3675133
Drug: 1.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 mL/kg of ethanol
Study: 30944165
Drug: Concurrent focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent focal noninvasive transcranial magnetic stimulation and electroencephalography
Study: 30944165
Drug: Psychotherapy (best-validated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (best-validated treatment for PTSD)
Study: 27631861
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy with reflective practice by therapists
Study: 27631861
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy without consideration of group dynamics
Study: 24983187
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg spironolactone (MRB group)
Study: 24983187
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril (RASB group)
Study: 18547863
Drug: No recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recovery treatment (control)
Study: 12461195
Drug: DISH administered
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DISH administered by research nurses
Study: 7762527
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of iodized oil A (490 mg I)
Study: 7762527
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of iodized oil A (2 x 245 mg I)
Study: 7762527
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of iodized oil B (675 mg I)
Study: 7762527
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose of oil A (2 x 245 mg I)
Study: 2065322
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine plus cyclophosphamide (300 mg/m2 i.v. 3 days prior to each vaccine immunization)
Study: 2065322
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine alone
Study: 2065322
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine plus cyclophosphamide
Study: 6634945
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 0.5 W/cm2
Study: 6634945
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 1.0 W/cm2
Study: 6634945
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 1.5 W/cm2
Study: 6634945
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatment at 0.0 W/cm2
Study: 24105031
Drug: U‐cas supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐cas supplementation at 180 g/kg DM in feed block (FB)
Study: 24105031
Drug: U‐cas supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐cas supplementation at 180 g/kg DM in FB
Study: 24105031
Drug: U‐cas supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐cas supplementation at 150 g/kg DM in FB
Study: 24105031
Drug: U‐cas supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐cas supplementation at 120 g/kg DM in FB
Study: 24105031
Drug: U‐cas supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: U‐cas supplementation at 0 g/kg DM in FB
Study: 11845362
Drug: Early PDL
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early PDL therapy for capillary haemangiomas
Study: 11845362
Drug: PDL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL treatment for mixed haemangiomas
Study: 2171853
Drug: Protein-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich meal (50 g of bovine serum albumin added)
Study: 7274405
Drug: time-limited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: time-limited therapy of 6 sessions within 8 weeks
Study: 7274405
Drug: time-limited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: time-limited therapy of 12 sessions within 16 weeks
Study: 7274405
Drug: time-unlimited therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: time-unlimited therapy
Study: 30422243
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks)
Study: 30422243
Drug: Dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks)
Study: 28954982
Drug: Intramuscle injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscle injection of testosterone enanthate
Study: 25209610
Drug: Trimethoprim/sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day)
Study: 25209610
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg twice a day)
Study: 21257057
Drug: GLP-2 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA) given subcutaneously every 12h for 10 days
Study: 21257057
Drug: GLP-2 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA)
Study: 17704418
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy regimens (including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel)
Study: 15221881
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training with creatine supplementation (5 g/day)
Study: 11848236
Drug: Topical lignocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine/prilocaine
Study: 27614164
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local treatment (Control)
Study: 9576390
Drug: RRV‐TV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐TV vaccine (titer 4 x 10(5) plaque‐forming units)
Study: 27142710
Drug: secukinumab 10
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: secukinumab 10 mg/kg
Study: 21908446
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 250 mg acetylsalicylic acid (ASA) + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Study: 11084060
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 5‐ to 10‐mg load, 1 to 4 mg/d